AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny

Postautor: slayer74 » 01 lis 2020 14:53

Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

REKLAMA


slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 03 lut 2021 13:51

EPS / Forecast
2.92 / 2.85

Revenue / Forecast
13.86B / 13.69B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 01 maja 2021 18:13

AbbVie Stock Nears Breakout After First-Quarter Beat And Raise

AbbVie (ABBV) delivered a better-than-expected first-quarter report on the back of its aesthetics business and raised its 2021 profit outlook. AbbVie stock inched higher Friday.

The strong beat was refreshing "on the heels of multiple disappointing first-quarter earnings results from large-cap biopharma companies," Mizuho Securities analyst Vamil Divan said in a report to clients.

Not only did sales and earnings beat, the company said it expects to launch five products this year.

"With a diversified new product story, robust near-term growth and good visibility into its longer-term growth prospects, we continue to see AbbVie as an especially compelling investment opportunity, especially when one considers the discount it trades at and its robust dividend," Divan said.

SAVE $78 ON YOUR IBD® SUBSCRIPTION!
Switch to a yearly membership today and take over 20% OFF your bill.
CLAIM OFFER!
He reiterated his buy rating and 126 price target on AbbVie stock. On the stock market today, AbbVie stock rose fractionally to 111.50. Shares are forming a flat base with a buy point at 113.51, according to MarketSmith.com.

AbbVie Stock: Earnings, Sales Beat
Overall, AbbVie earnings jumped 22% to $2.95 per share, minus some items. That easily beat the FactSet estimate for $2.81 a share. The company generated $13.01 billion in sales, surging 51% year over year and topping the $12.77 billion forecast.

The aesthetics business — which AbbVie bought with Allergan — generated north of $1.14 billion in sales. That included $477 million in sales of Botox as a cosmetic treatment. The same drug is used to treat several medical conditions. There, it brought in $532 million.

Piper Sandler analyst Christopher Raymond noted aesthetics sales beat forecasts by $167 million. The company's immunology franchise, which includes major blockbuster Humira, also topped expectations by $93 million.

Worldwide, Humira generated $4.87 billion in sales, inching 3.5% higher. In the U.S., the drug brought in $3.91 billion, up 6.9%. Global Humira sales topped expectations, though U.S. sales were light, Raymond said.

Still, "with the backdrop of other large caps highlighting Covid and pricing headwinds as drivers of weak first-quarter numbers, we think this print is likely to raise an eyebrow or two," he said. Raymond has an overweight rating and 120 price target on AbbVie stock.

For the year, AbbVie now expects adjusted income of $12.37-$12.57 per share. At the midpoint, that beat AbbVie stock analysts' call for $12.39 per share on $55.4 billion in sales.

https://www.investors.com/news/technolo ... s-q1-2021/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 18 cze 2021 01:30

Abbvie(ABBV) analiza spółki 13.06.2021 by Bartek Szyma
https://www.youtube.com/watch?v=NDTsc1gvA1Y&t=517s

2023 wygaśnie patent na lek Humira, który generuje największe przychody
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 30 lip 2021 17:19

AbbVie raises annual profit forecast as Botox demand rebounds

(Reuters) -Drugmaker AbbVie Inc (NYSE:ABBV) raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira.

Sales of Botox for cosmetic use rose two-fold to $584 million in the second quarter to trounce estimates of $483 million, as vaccinations encouraged people to step out more and resume non-essential procedures after being holed up at home for months.

The company grabbed Botox last year as part of its $63 billion purchase of Allergan (NYSE:AGN), a move aimed at cushioning the hit from the looming loss of U.S. patents for the world's best-selling drug Humira, expected in 2023.

Sales of Humira, a treatment for rheumatoid arthritis and which is already facing rivals in Europe, rose 4.8% to $5.07 billion, roughly in line with a Refinitiv IBES estimate of $5.08 billion.

But sales of the drug fell 6% on a reported basis in international markets while rising 7.1% in the United States.

The strong quarter was mainly driven by multiple Allergan products, while sales of core AbbVie assets came in fairly close to expectations, Mizuho analyst Vamil Divan said.

AbbVie said it expects full-year adjusted earnings between $12.52 and $12.62 per share, compared with $12.37 to $12.57 per share previously. Analysts expected 2021 earnings per share of $12.61.

The company's quarterly results were also underpinned by two-fold jumps in sales of psoriasis drug Skryizi and rheumatoid arthritis treatment Rinvoq. AbbVie has focused on expanding the use of the drugs to soften the expected blow to Humira sales.

The company swung to a profit of $766 million from a loss of $738 million a year earlier. Excluding one-time items, it earned $3.11 per share.

A Refinitiv tally showed AbbVie earned $3.09 per share, meeting estimates.

(Reuters) -Drugmaker AbbVie Inc (NYSE:ABBV) raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira.

Sales of Botox for cosmetic use rose two-fold to $584 million in the second quarter to trounce estimates of $483 million, as vaccinations encouraged people to step out more and resume non-essential procedures after being holed up at home for months.

The company grabbed Botox last year as part of its $63 billion purchase of Allergan (NYSE:AGN), a move aimed at cushioning the hit from the looming loss of U.S. patents for the world's best-selling drug Humira, expected in 2023.

Sales of Humira, a treatment for rheumatoid arthritis and which is already facing rivals in Europe, rose 4.8% to $5.07 billion, roughly in line with a Refinitiv IBES estimate of $5.08 billion.

But sales of the drug fell 6% on a reported basis in international markets while rising 7.1% in the United States.

The strong quarter was mainly driven by multiple Allergan products, while sales of core AbbVie assets came in fairly close to expectations, Mizuho analyst Vamil Divan said.

AbbVie said it expects full-year adjusted earnings between $12.52 and $12.62 per share, compared with $12.37 to $12.57 per share previously. Analysts expected 2021 earnings per share of $12.61.

The company's quarterly results were also underpinned by two-fold jumps in sales of psoriasis drug Skryizi and rheumatoid arthritis treatment Rinvoq. AbbVie has focused on expanding the use of the drugs to soften the expected blow to Humira sales.

The company swung to a profit of $766 million from a loss of $738 million a year earlier. Excluding one-time items, it earned $3.11 per share.

A Refinitiv tally showed AbbVie earned $3.09 per share, meeting estimates.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 26 wrz 2021 20:00

Undervalued Dividend Growth Stock of the Week 2019/06/23
https://dailytradealert.com/2019/06/23/ ... -week-215/
Obrazek

AbbVie SWOT Analysis
https://seekingalpha.com/article/427158 ... ngcom_feed
Undervalued Dividend Growth Stock of the Week: AbbVie (ABBV) 2020/11/01
https://dailytradealert.com/2020/11/01/ ... bvie-abbv/
Obrazek

https://www.youtube.com/watch?v=wF2vBDg ... sAndIncome
Undervalued Dividend Growth Stock of the Week: AbbVie (ABBV)
by Jason Fieber, Mr. Free at 33 • September 26, 2021

Obrazek

https://www.youtube.com/watch?v=m_v5DcYlfaE

https://dailytradealert.com/2021/09/26/ ... ie-abbv-2/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 31 paź 2021 08:47

Latest Release
Oct 29, 2021

EPS / Forecast
3.33 / 3.21

Revenue / Forecast
14.34B / 14.3B

AbbVie (ABBV) reported EPS rose 18% with sales up 11% to $14.34 billion. The medical products giant also raised its full-year EPS outlook.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 14 lis 2021 17:41

dywidendy
TURBO Dividend! This Stock Pays a High-Yield of 5.5% and Pays Out Monthly!

https://www.youtube.com/watch?v=3dB4srzDj5s
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 08 maja 2022 17:15

AbbVie (ABBV) downgraded by Daiwa from Outperform to Neutral
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 12 lut 2023 09:35

Latest Release
Feb 09, 2023

EPS / Forecast
3.6 / 3.53

Revenue / Forecast
15.12B / 15.33B

AbbVie (ABBV) popped on a better-than-feared outlook for 2023
profit. Q4 profit beat with a 17%
drop. Sales missed estimates, but
rose 2% to $15.12 billion
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 27 kwie 2023 16:29

Latest Release
Apr 27, 2023

EPS / Forecast
2.46 / 2.46

Revenue / Forecast
12.23B / 12.18B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 27 kwie 2023 20:05

AbbVie (NYSE:ABBV) shares are tumbling premarket, currently down over 6% after the company reported its first-quarter earnings, which saw it report in-line profits and a revenue beat but miss sales estimates for some of its major drugs.

The company reported Q1 EPS of $2.46, in line with the analyst estimate of $2.46, while revenue, which fell more than 9% YoY, came in at $12.23 billion, topping the consensus estimate of $12.18 billion.

However, ABBV's sales of Humira came in at $3.54B, below the consensus estimate of $3.58B, according to Reuters, using data from Refinitiv IBES. In addition, Rinvoq's revenues were $686M, which Reuters reported was lower than the consensus estimate of $713.7M.

Nevertheless, ABBV chairman and chief executive officer Richard Gonzalez struck a positive tone: "This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio."

Looking ahead, the company sees FY2023 earnings between $10.72 and $11.12 per share versus the consensus of $10.94.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: AbbVie Inc. NYSE: ABBV p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 27 lip 2023 14:10

Latest Release
Jul 27, 2023

EPS / Forecast
2.91 / 2.87

Revenue / Forecast
13.87B / 13.51B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 21 gości